This conference room is supported by funding from Biogen.

Biogen and the University at Buffalo have collaborated successfully for over two decades. In the early 1990s, the company supported clinical trials led by Lawrence Jacobs, MD, a pioneering neurologist in the Jacobs School of Medicine and Biomedical Sciences. Building on Jacobs’ research, the trials proved genetically engineered interferon beta-1a an effective treatment for some forms of multiple sclerosis. Approved by the U.S. Food and Drug Administration in 1996, the breakthrough drug is marketed by the company under the brand name AVONEX®.

Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs.